Global Chemotherapy Treatment Market 2019-2023
SKU ID : TNV-14253031 | Publishing Date : 08-May-2019 | No. of pages : 136
Detailed TOC of Global Chemotherapy Treatment Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY DRUG CLASS
Market segmentation by drug class
Comparison by drug class
Antimetabolites - Market size and forecast 2018-2023
Plant derivatives - Market size and forecast 2018-2023
Cytotoxic antibiotics - Market size and forecast 2018-2023
Alkylating agents - Market size and forecast 2018-2023
Others - Market size and forecast 2018-2023
Market opportunity by drug class
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Market trends
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Bristol-Myers Squibb Co.
Eli Lilly and Co.
Johnson & Johnson Services Inc.
Novartis AG
Pfizer Inc.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Combination therapy approvals
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Drug class - Market share 2018-2023 (%)
Exhibit 19: Comparison by drug class
Exhibit 20: Antimetabolites - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antimetabolites - Year-over-year growth 2019-2023 (%)
Exhibit 22: Plant derivatives - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Plant derivatives - Year-over-year growth 2019-2023 (%)
Exhibit 24: Cytotoxic antibiotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Cytotoxic antibiotics - Year-over-year growth 2019-2023 (%)
Exhibit 26: Alkylating agents - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Alkylating agents - Year-over-year growth 2019-2023 (%)
Exhibit 28: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Others - Year-over-year growth 2019-2023 (%)
Exhibit 30: Market opportunity by drug class
Exhibit 31: Customer landscape
Exhibit 32: Market share by geography 2018-2023 (%)
Exhibit 33: Geographic comparison
Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Approvals of chemotherapeutics
Exhibit 45: Side-effects of chemotherapy drugs
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Combination therapies under late-stage clinical trials
Exhibit 48: Repurposed chemotherapy agents
Exhibit 49: Antibody drug conjugates undergoing clinical trials
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 56: Bristol-Myers Squibb Co. - Business segments
Exhibit 57: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 58: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 59: Bristol-Myers Squibb Co. - Key offerings
Exhibit 60: Eli Lilly and Co. - Vendor overview
Exhibit 61: Eli Lilly and Co. - Business segments
Exhibit 62: Eli Lilly and Co. - Organizational developments
Exhibit 63: Eli Lilly and Co. - Geographic focus
Exhibit 64: Eli Lilly and Co. - Segment focus
Exhibit 65: Eli Lilly and Co. - Key offerings
Exhibit 66: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 67: Johnson & Johnson Services Inc. - Business segments
Exhibit 68: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 69: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 70: Johnson & Johnson Services Inc. - Segment focus
Exhibit 71: Johnson & Johnson Services Inc. - Key offerings
Exhibit 72: Novartis AG - Vendor overview
Exhibit 73: Novartis AG - Business segments
Exhibit 74: Novartis AG - Organizational developments
Exhibit 75: Novartis AG - Geographic focus
Exhibit 76: Novartis AG - Segment focus
Exhibit 77: Novartis AG - Key offerings
Exhibit 78: Pfizer Inc. - Vendor overview
Exhibit 79: Pfizer Inc. - Business segments
Exhibit 80: Pfizer Inc. - Organizational developments
Exhibit 81: Pfizer Inc. - Geographic focus
Exhibit 82: Pfizer Inc. - Segment focus
Exhibit 83: Pfizer Inc. - Key offerings
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
Keyplayers in Global Chemotherapy Treatment Market 2019-2023
Bristol-Myers Squibb Co.Eli Lilly and Co.
Johnson & Johnson Services Inc.
Novartis AG
Pfizer Inc.